Bonesupport Holding AB

Bonesupport Holding AB

Health CarePharmaceuticals and Biotechnology
  • Price (SEK)115.30
  • Today's Change0.300 / 0.26%
  • Shares traded85.58k
  • 1 Year change+106.08%
  • Beta0.8780
Data delayed at least 15 minutes, as of May 29 2023 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.

  • Revenue in SEK (TTM)382.22m
  • Net income in SEK-51.49m
  • Incorporated2010
  • Employees101.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Ultimovacs ASA0.00-161.02m3.95bn24.00--9.58-----4.82-4.820.0012.300.00----0.00-30.14-25.92-32.89-27.77------------0.0118-------1.86--56.16--
MedCap AB (publ)1.11bn117.50m4.66bn368.0039.705.4522.644.207.947.9475.0457.830.85523.717.233,019,565.009.087.7011.5110.7147.8145.2610.628.461.928.990.28360.0021.28--21.87------
Calliditas Therapeutics AB944.50m-392.75m5.66bn181.00--8.65--5.99-7.35-7.3517.7110.980.60293.5516.309,259,775.00-25.07-27.85-29.58-30.9597.50---41.58-125.043.89-31.870.5589--250.07--17.59------
Swedencare AB (publ)1.98bn86.32m7.41bn490.0085.540.997220.453.750.54610.546112.4946.840.20652.099.234,069,475.000.90112.370.93722.4655.5256.054.367.672.292.460.202836.63137.2384.6372.9240.89137.91--
Bonesupport Holding AB382.22m-51.49m7.48bn101.00--27.96--19.57-0.7981-0.79815.924.111.080.66626.514,246,867.00-14.53-32.63-18.67-40.5290.5388.89-13.47-60.803.09-404.370.0568--54.4620.5220.30---6.59--
Nykode Therapeutics ASA103.35m-498.55m8.14bn158.00--5.09--78.79-1.74-1.740.36135.560.0417--7.63684,474.80-20.1211.35-23.3912.68-----482.4329.70----0.0358---78.89161.32-354.04--212.66--
BioGaia AB1.19bn413.42m9.76bn211.0024.504.8522.,593,977.0018.1617.0219.6218.9172.7173.6034.8627.77----0.0074.2040.6112.4190.4415.66-7.6210.01
Data as of May 29 2023. Currency figures normalised to Bonesupport Holding AB's reporting currency: Swedish Krona SEK

Institutional shareholders

37.42%Per cent of shares held by top holders
HolderShares% Held
Swedbank Robur Fonder ABas of 28 Apr 20236.09m9.37%
Fj�rde AP-fondenas of 28 Nov 20223.22m4.95%
Capital Research & Management Co. (World Investors)as of 31 Mar 20232.90m4.45%
Tredje AP-fondenas of 28 Nov 20222.82m4.33%
Financi�re de l'�chiquier SAas of 30 Jun 20222.52m3.87%
Lancelot Asset Management ABas of 28 Nov 20222.40m3.69%
Norges Bank Investment Managementas of 28 Nov 20221.64m2.53%
Handelsbanken Fonder ABas of 30 Apr 20231.21m1.85%
Carnegie Fonder ABas of 28 Apr 2023833.55k1.28%
AXA Investment Managers (Paris) SAas of 30 Sep 2022720.00k1.11%
More ▼
Data from 30 Jun 2022 - 28 Apr 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.